Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Gross Profit (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Gross Profit for 5 consecutive years, with $52.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Gross Profit rose 37.87% to $52.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $170.3 million, a 45.83% increase, with the full-year FY2025 number at $170.3 million, up 45.83% from a year prior.
  • Gross Profit was $52.5 million for Q4 2025 at Rhythm Pharmaceuticals, up from $45.8 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $52.5 million in Q4 2025 to a low of -$9.1 million in Q4 2022.
  • A 5-year average of $17.8 million and a median of $18.5 million in 2023 define the central range for Gross Profit.
  • Biggest YoY gain for Gross Profit was 3990.32% in 2022; the steepest drop was 674.07% in 2022.
  • Rhythm Pharmaceuticals' Gross Profit stood at $1.6 million in 2021, then crashed by 674.07% to -$9.1 million in 2022, then soared by 331.39% to $21.0 million in 2023, then skyrocketed by 81.15% to $38.0 million in 2024, then surged by 37.87% to $52.5 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Gross Profit are $52.5 million (Q4 2025), $45.8 million (Q3 2025), and $43.0 million (Q2 2025).